-
Lava Therapeutics NASDAQ:LVTX
Location: | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-27.12M
Cash
86.8M
Avg Qtr Burn
-6.77M
Short % of Float
0.02%
Insider Ownership
28.72%
Institutional Own.
32.62%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
LAVA-1207 Details Cancer, Solid tumor/s, Prostate cancer, Prostate disease, Castration-resistant prostate cancer | Phase 1/2 Data readout | |
SGN-EGFRd2 (LAVA-1223) Details Cancer, Solid tumor/s | Phase 1 Data readout | |
LAVA-1266 Details Cancer, Hematologic malignancies, Acute myeloid leukemia, Myelodysplastic syndrome | Phase 1 Initiation | |
LAVA-051 ( gamma-delta bsTCE targeting CD1d-expressing tumors) Details Solid tumor/s, Cancer, Chronic lymphocytic leukemia, Acute myeloid leukemia, Multiple myeloma | Failed Discontinued |